

REFERENCES

Adhikari, S. P., Meng, S., Wu, Y. J., Mao, Y. P., Ye, R. X., Wang, Q. Z., Sun, C., Sylvia, S., Rozelle, S., Raat, H., & Zhou, H. (2020). Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: a scoping review. *Infectious diseases of poverty*, 9(1), 29.

Adriaenssens, N., Coenen, S., Tonkin-Crine, S., Verheij, T. J., Little, P., & Goossens, H. (2011). European Surveillance of Antimicrobial Consumption (ESAC): disease-specific quality indicators for outpatient antibiotic prescribing. *BMJ quality & safety*, 20(9), 764-772.

Ai, T., Yang, Z., Hou, H., Zhan, C., Chen, C., Lv, W., Tao, Q., Sun, Z., & Xia, L. (2020). Correlation of Chest CT and RT-PCR Testing for Coronavirus Disease 2019 (COVID-19) in China: A Report of 1014 Cases. *Radiology*, 296(2), E32–E40.

Al-Tawfiq, J. A., Al-Homoud, A. H., & Memish, Z. A. (2020). Remdesivir as a possible therapeutic option for the COVID-19. *Travel medicine and infectious disease*, 34, 101615.

Albert, R. K., Connett, J., Bailey, W. C., Casaburi, R., Cooper Jr, J. A. D., Criner, G. J., ... & Anthonisen, N. R. (2011). Azithromycin for prevention of exacerbations of COPD. *New England Journal of Medicine*, 365(8), 689-698.

Blondeau, J. M., DeCarolis, E., Metzler, K. L., & Hansen, G. T. (2002). The macrolides. *Expert opinion on investigational drugs*, 11(2), 189-215.

Brooks, S. K., Webster, R. K., Smith, L. E., Woodland, L., Wessely, S., Greenberg, N., & Rubin, G. J. (2020). The psychological impact of quarantine and how to reduce it: rapid review of the evidence. *The lancet*, 395(10227), 912-920.

Cao, B., Wang, Y., Wen, D., Liu, W., Wang, J., Fan, G., ... & Wang, C. (2020). A trial of lopinavir–ritonavir in adults hospitalized with severe Covid-19. *New England journal of medicine*.

Carta, M., Pascarella, M., Cappelletti, A., Rassu, M., & Giavarina, D. (2022). Evaluating the role of a fully automated SARS-CoV-2 antigen ECLIA immunoassay in the management of the SARS COV 2 pandemic on general population. *Diagnosis*, 9(4), 491-498.

Chan, J. F. W., Yuan, S., Kok, K. H., To, K. K. W., Chu, H., Yang, J., ... & Yuen, K. Y. (2020). A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. *The lancet*, 395(10223), 514-523.

Echeverría-Esnal, D., Martín-Ontiyuelo, C., Navarrete-Rouco, M. E., De-Antonio Cusco, M., Ferrández, O., Horcajada, J. P., & Grau, S. (2021). Azithromycin in the treatment of COVID-19: a review. *Expert review of anti-infective therapy*, 19(2), 147-163.

Fathi, M., Vakili, K., Sayehmiri, F., Mohamadkhani, A., Hajiesmaeili, M., Rezaei-Tavirani, M., & Eilami, O. (2021). The prognostic value of comorbidity for the severity of COVID-19: A systematic review and meta-analysis study. *PloS one*, 16(2), e0246190

Gautret, P., Lagier, J. C., Parola, P., Hoang, V. T., Meddeb, L., Mailhe, M., ... & Vieira, V. E. (2020). Hervé Tissot Dupont, Stéphane Honofe, Philippe Colson, EricChabriere, Bernard La Scola, Jean-Marc Rolain, Philippe Brouqui, Didier Raoult, Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. *Int J Antimicrob Agents*, 56(1), 105949.

Guan, W. J., Ni, Z. Y., Hu, Y., Liang, W. H., Ou, C. Q., He, J. X., ... & Zhong, N. S. (2020). Clinical characteristics of coronavirus disease 2019 in China. *New England journal of medicine*, 382(18), 1708-1720.

Horby, P. W., Mafham, M., Bell, J. L., Linsell, L., Staplin, N., Emberson, J., ... & Landray, M. J. (2020). Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. *The Lancet*, 396(10259), 1345-1352.

Kang, I. S., & Kong, K. A. (2021). Body mass index and severity/fatality from coronavirus disease 2019: A nationwide epidemiological study in Korea. *PloS one*, 16(6), e0253640.

Kang, T., Lu, J., Yu, T., Long, Y., & Liu, G. (2022). Advances in nucleic acid amplification techniques (NAATs): COVID-19 point-of-care diagnostics as an example. *Biosensors and Bioelectronics*, 114109.

Kordzadeh-Kermani, E., Khalili, H., & Karimzadeh, I. (2020). Pathogenesis, clinical manifestations and complications of coronavirus disease 2019 (COVID-19). *Future microbiology*, 15, 1287–1305. <https://doi.org/10.2217/fmb-2020-0110>

Kruglikov, I. L., & Scherer, P. E. (2020). The Role of Adipocytes and Adipocyte-Like Cells in the Severity of COVID-19 Infections. *Obesity (Silver Spring, Md.)*, 28(7), 1187–1190. <https://doi.org/10.1002/oby.22856>

Li, C., Zu, S., Deng, Y. Q., Li, D., Parvatiyar, K., Quanquin, N., ... & Cheng, G. (2019). Azithromycin protects against Zika virus infection by upregulating virus-induced type I and III interferon responses. *Antimicrobial agents and chemotherapy*, 63(12), e00394-19.

Li, Qun & Guan, Xuhua & Wu, Peng & Wang, Xiaoye & Zhou, Lei & Tong, Yeqing & Ren, Ruiqi & Leung, Kathy & Lau, Eric & Wong, Jessica Y & Xing, Xuesen &

Xiang, Nijuan & Wu, Yang & Li, Chao & Chen, Qi & Li, Dan & Liu, Tian & Zhao, Jing & Li, Man & Feng, Zijian. (2020). Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia. *New England Journal of Medicine*. 382. 10.1056/NEJMoa2001316.

Lombardia, S. R. (2020). *Vademecum per la cura delle persone con malattia da COVI-19*. Società Italiana di Malattie Infettive e Tropicali: Prato, Italy.

Mackay, I. M., Arden, K. E., & Nitsche, A. (2002). Real-time PCR in virology. *Nucleic acids research*, 30(6), 1292–1305. <https://doi.org/10.1093/nar/30.6.1292>

MaxCmin2 trial group, Dragsted, U. B., Gerstoft, J., Youle, M., Fox, Z., Losso, M., ... & Lundgren, J. D. (2005). A randomized trial to evaluate lopinavir/ritonavir versus saquinavir/ritonavir in HIV-1-infected patients: the MaxCmin2 trial. *Antiviral therapy*, 10(6), 735-743.

Mazzei, T., Surrenti, C., Novelli, A., Crispo, A., Fallani, S., Carla, V., ... & Periti, P. (1993). Pharmacokinetics of azithromycin in patients with impaired hepatic function. *Journal of Antimicrobial Chemotherapy*, 31(suppl_E), 57-63.

Meini, S., Pagotto, A., Longo, B., Vendramin, I., Pecori, D., & Tascini, C. (2020). Role of Lopinavir/Ritonavir in the Treatment of Covid-19: A Review of Current Evidence, Guideline Recommendations, and Perspectives. *Journal of clinical medicine*, 9(7), 2050. <https://doi.org/10.3390/jcm9072050>

Million, M., Lagier, J. C., Gautret, P., Colson, P., Fournier, P. E., Amrane, S., ... & Raoult, D. (2020). Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: a retrospective analysis of 1061 cases in Marseille, France. *Travel medicine and infectious disease*, 35, 101738.

Ng, Ming-Yen & Lee, Elaine & Yang, Jin & Yang, Fangfang & Li, Xia & Wang, Hongxia & Lui, Macy & Lo, Christine & Leung, Barry Siu Ting & Khong, Pek &

Hui, Christopher & Yuen, Kwok-yung & Kuo, Mike. (2020). Imaging Profile of the COVID-19 Infection: Radiologic Findings and Literature Review. *Radiology: Cardiothoracic Imaging*. 2. e200034. 10.1148/ryct.2020200034.

Oliveira, B. A., Oliveira, L. C. D., Sabino, E. C., & Okay, T. S. (2020). SARS-CoV-2 and the COVID-19 disease: a mini review on diagnostic methods. *Revista do Instituto de Medicina Tropical de São Paulo*, 62.

Parnham, M. J., Haber, V. E., Giamarellos-Bourboulis, E. J., Perletti, G., Verleden, G. M., & Vos, R. (2014). Azithromycin: mechanisms of action and their relevance for clinical applications. *Pharmacology & therapeutics*, 143(2), 225-245.

Perlman, S. (2020). Another decade, another coronavirus. *New England Journal of Medicine*, 382(8), 760-762.

Rachman, B. E., Miatmoko, A., Lardo, S., Purnama, Y. I., Laely, M., Rochmad, I., ... & Indrayani, Y. (2021). A randomized, double-blind, multicenter clinical study comparing the efficacy and safety of a drug combination of lopinavir/ritonavir-azithromycin, lopinavir/ritonavir-doxycycline, and azithromycin-hydroxychloroquine for patients diagnosed with mild to moderate COVID-19 infections. *Biochemistry research international*, 2021.

Sanchis-Gomar, F., Lavie, C. J., Mehra, M. R., Henry, B. M., & Lippi, G. (2020). Obesity and Outcomes in COVID-19: When an Epidemic and Pandemic Collide. *Mayo Clinic proceedings*, 95(7), 1445–1453. <https://doi.org/10.1016/j.mayocp.2020.05.006>

Sanyaolu, A., Okorie, C., Marinkovic, A., Patidar, R., Younis, K., Desai, P., ... & Altaf, M. (2020). Comorbidity and its impact on patients with COVID-19. *SN comprehensive clinical medicine*, 2, 1069-1076.

Sekhavati, E., Jafari, F., Seyed Alinaghi, S., Jamali Moghadam Siahkali, S., Sadr, S., Tabarestani, M., ... & Ghiasvand, F. (2020). Safety and effectiveness of azithromycin in patients with COVID-19: an open-label randomised trial. *International journal of antimicrobial agents*, 56(4), 106143.

Wages J. M., Jr. (2005). POLYMERASE CHAIN REACTION. *Encyclopedia of Analytical Science*, 243–250. <https://doi.org/10.1016/B0-12-369397-7/00475-1>

Wang, B., Li, R., Lu, Z., & Huang, Y. (2020). Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis. *Aging (albany NY)*, 12(7), 6049.

Wang, W., Xu, Y., Gao, R., Lu, R., Han, K., Wu, G., & Tan, W. (2020). Detection of SARS-CoV-2 in different types of clinical specimens. *Jama*, 323(18), 1843-1844.

Wingert, A., Pillay, J., Gates, M., Guitard, S., Rahman, S., Beck, A., ... & Hartling, L. (2021). Risk factors for severity of COVID-19: a rapid review to inform vaccine prioritisation in Canada. *BMJ open*, 11(5), e044684.

World Health Organization. (n.d.). Laboratory testing of 2019 novel coronavirus (2019-ncov) in suspected human cases: Interim guidance, 17 January 2020. World Health Organization. Retrieved August 3, 2022, from [https://www.who.int/publications/i/item/laboratory-testing-of-2019-novel-coronavirus-\(-2019-ncov\)-in-suspected-human-cases-interim-guidance-17-january-2020](https://www.who.int/publications/i/item/laboratory-testing-of-2019-novel-coronavirus-(-2019-ncov)-in-suspected-human-cases-interim-guidance-17-january-2020)

Zhuang, G. H., Shen, M. W., Zeng, L. X., Mi, B. B., Chen, F. Y., Liu, W. J., ... & Li, C. (2020). WITHDRAWN: Potential false-positive rate among the 'asymptomatic infected individuals' in close contacts of COVID-19 patients. *Zhonghua liu xing bing xue za zhi= Zhonghua liuxingbingxue zazhi*, 41(4), 485-488.